Format

Send to

Choose Destination
Maturitas. 2009 Jul 20;63(3):240-5. doi: 10.1016/j.maturitas.2009.03.020. Epub 2009 May 1.

The safety of 52 weeks of oral DHEA therapy for postmenopausal women.

Author information

1
NH&MRC Centre of Clinical Research Excellence in the Women's Health Program, Department of Medicine, Central and Eastern Clinical School, Monash University, Alfred Hospital, Prahran, Victoria, Australia. mary.panjari@med.monash.edu.au

Abstract

OBJECTIVE:

The aim of this study was to evaluate the safety of 52 weeks of DHEA 50mg daily oral dose given to postmenopausal women with low libido to improve sexual function.

METHOD:

93 postmenopausal women were enrolled in a 52-week randomised, double-blind, placebo-controlled trial and received either DHEA 50mg or placebo (PL) daily. The effects of DHEA versus placebo on lipid profile, insulin-glucose homeostasis and the endomentrium were assessed over 52 weeks.

RESULTS:

Oral DHEA, 50mg/day, was not associated with any effects on blood lipids or insulin resistance. The pattern of breakthrough bleeding did not substantially differ between the DHEA and PL groups and no significant adverse endometrial effects were apparent.

CONCLUSIONS:

The use of 50mg oral DHEA did not significantly alter lipid profile, insulin sensitivity or adversely affect the endometrium in postmenopausal women.

PMID:
19410392
DOI:
10.1016/j.maturitas.2009.03.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center